Actinium Pharmaceuticals, Inc. financial data

Symbol
ATNM on NYSE
Industry
Pharmaceutical Preparations
Location
100 Park Ave., 23 Rd Floor, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Cactus Ventures, Inc. (to 3/29/2013)
Latest financial report
Q1 2024 - Apr 26, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1K % -24.7%
Debt-to-equity 102 % +53.7%
Return On Equity -57 % -75.8%
Return On Assets -51.9 % -51.7%
Operating Margin -64.1K % -1836%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.4M shares +14.3%
Common Stock, Shares, Outstanding 29.4M shares +14.3%
Entity Public Float 200M USD +67.5%
Common Stock, Value, Issued 29K USD +11.5%
Weighted Average Number of Shares Outstanding, Basic 27.9M shares +8.52%
Weighted Average Number of Shares Outstanding, Diluted 27.9M shares +8.52%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 81K USD -92.1%
Research and Development Expense 37.5M USD +40.7%
General and Administrative Expense 12.6M USD -10.3%
Operating Income (Loss) -49.9M USD -23.2%
Nonoperating Income (Expense) 3.48M USD +118%
Net Income (Loss) Attributable to Parent -46.5M USD -19.3%
Earnings Per Share, Basic -1.71 USD/shares -8.92%
Earnings Per Share, Diluted -1.71 USD/shares -8.92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.1M USD -11.1%
Other Assets, Current 226K USD +248%
Assets, Current 85.4M USD -13.4%
Property, Plant and Equipment, Net 496K USD -21.3%
Operating Lease, Right-of-Use Asset 2.14M USD -15.9%
Assets 88.4M USD -13.4%
Liabilities, Current 8.06M USD +2.54%
Operating Lease, Liability, Noncurrent 1.41M USD
Liabilities 44.5M USD -0.72%
Retained Earnings (Accumulated Deficit) -346M USD -15.5%
Stockholders' Equity Attributable to Parent 43.9M USD -23.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 57.2M USD -16.9%
Liabilities and Equity 88.4M USD -13.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.37M USD +51.1%
Net Cash Provided by (Used in) Financing Activities 14.8M USD +1818%
Net Cash Provided by (Used in) Investing Activities -11K USD +85.5%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 29.4M shares +14.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.4M USD -148%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 84.4M USD -11.4%
Deferred Tax Assets, Valuation Allowance 90.6M USD +19%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 1.95M USD
Depreciation 207K USD +36.2%
Payments to Acquire Property, Plant, and Equipment 11K USD -85.5%
Lessee, Operating Lease, Liability, to be Paid 2.12M USD
Operating Lease, Liability, Current 540K USD +7.36%
Lessee, Operating Lease, Liability, to be Paid, Year Two 630K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 466K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 165K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 643K USD
Deferred Tax Assets, Operating Loss Carryforwards 41.7M USD -5.73%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 380K USD
Operating Lease, Payments 153K USD +2%
Additional Paid in Capital 390M USD +9.27%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 89K USD -84.2%
Share-based Payment Arrangement, Expense 6K USD -62.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%